Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PHRM 864 > L immunology oncology > Flashcards

L immunology oncology Flashcards

1
Q

Antibody producing cells:
A. T cells
B. NK cells
C. B cells
D. Gay cells

A

C. B cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Fully human
A. -o
B. -xi
C. -zu
D. -u

A

D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Humanized
A. -o
B. -xi
C. -zu
D. -u

A

C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Mouse
A. -o
B. -xi
C. -zu
D. -u

A

A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Chimeric
A. -o
B. -xi
C. -zu
D. -u

A

B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

T or F:
HER2 is genomically amplified in breast cancer

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Trastuzumab more commonly known name

A

herceptin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Trastuzumab is a recombinant _________ mab specific for ____

A

humanized
HER2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Trastuzumab binds to receptor and induces antibody-dependent cellular _______

A

cytotoxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

primary indication of trastuzumab

A

breast cancers that overexpress HER2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

4 toxicities listed under trastuzumab

A

flu like sxs
risk of cardiomyopathy/CHF
increase in myelosuppression
hypersensitivity rxs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Pertuzumab binds to her2 and inhibits ______***

A

dimerization (which also inhibits kinase activity)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

T or F:
Pertuzumab and Trastuzumab are used in combination

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what was the significance of the CLEOPATRA trial?

A

using both antibodies (pertuz and trastuz) against HER2 increased efficacy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what does margetuximab target

A

HER2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Cetuximab class

A

EGFR antibody

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Cetuximab binds specifically to what

A

extracellular domain of the EGF receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

T or F:
Cetuximab is a competitive inhibitor

A

true

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Cetuximab competitively inhibits binding of ____ and ____

A

EGF
TGF-alpha

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

T or F:
Cetuximab blocks phosphorylation and activation of receptor-associated kinases **

A

true

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

primary indication of Cetuximab

A

tx of colorectal and head and neck cancers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

big all caps thing under toxicities for cetuximab

A

severe infusion reaction in ~3% of patients - usually first dose if that matters

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

T or F:
Panitumumab is fully humanized

A

true

24
Q

where does panitumumab bind?

A

extracellular domain of the EGF receptor

25
Q

primary indication of panitumumab

A

tx of colorectal cancer

26
Q

T or F:
Panitumumab carries the same infusion toxicities as cetuximab

A

false, it dont

27
Q

Bevacizumab is specific for ?

A

VEGF

28
Q

What is the significance of Bevacizumab binding VEGF?

A

It blocks endothelial cell proliferation and new blood vessel formation

29
Q

T or F:
There is no evidence of efficacy of Bevacizumab as a single agent

A

true

30
Q

Bevacizumab is used in combo with ______ based chemotherapy for 1st line tx of metastatic colorectal cancer

A

5-FU

31
Q

Binds VEGF:
A. Bevacizumab
B. Ramucirumab

A

A

32
Q

binds VEGFR
A. Bevacizumab
B. Ramucirumab

A

B

33
Q

Which of the following antibodies targets Her2?

A. Neratinib
B. Cetuximab
C. Lapatinib
D. Pertuzumab

A

D

34
Q

What was the first immunotherapy?

A. Pertuzumab
B. Keytruda
C. Coley’s toxin
D. Trastuzumab

A

my toxin

35
Q

The antibody Fakeumab has just entered the market. What type of the antibody was it?

A. Fully human
B. Humanized
C. Fully mouse
D. Chimeric

A

a

36
Q

T or F:
CD20 works with B-cell receptor to drive proliferation of B-cells

A

true

37
Q

T or F:
CD20 plays a role in the proliferation of B-cell lymphomas

A

true

38
Q

Rituximab is a _____ antibody

A

CD20

39
Q

what does rituximab bind to?

A

CD20

40
Q

Ofatumumab is a ________ antibody specific for _____ originally developed to treat multiple sclerosis and now used in CLL

A

fully human monoclonal
CD20

41
Q

Rituximab and Obinutuzumab are currently approved for what?

A

B-cell lymphomas (non-hodgkins lymphoma) that target different binding sites on CD20

42
Q

Daratumumab target

A

CD38

43
Q

Multiple myeloma is a cancer of __________ plasma cells

A

malignant

44
Q

CD38 is found on ______ cells that do not have _____ on their surface

A

plasma
CD20

45
Q

T or F:
Daratumumab also eliminates NK cells

A

true

46
Q

antibody drug-conjugates both have which drug involved

A

trastuzumab

47
Q

Trastuzumab Emtansine (TDM1) binds to what? What does this lead to?

A

HER2/Neu receptor
usual herceptin response

48
Q

T or F:
Emtansine is a cytotoxic agent

A

true

48
Q

Emtansine enters cells and _______ microtubule assembly

A

inhibits

49
Q

trastuzumab emtansine is approved for what

A

as a 2nd line tx for HER2-positive metastatic breast cancer

50
Q

3 toxicities listed under trastuzumab emtansine

A
  • adverse effects of trastuzumab
  • thrombocytopenia (mertansine)
  • Hepatotoxicity (mertansine)
51
Q

Another ADC is trastuzumab-deruxtecan. what class is deruxtecan?

A

TOPO I inhibitor

52
Q

negative selection of T-cells that bind to “self” peptides in the thymus:
A. central tolerance
B. peripheral tolerance

A

A central

53
Q

self reactive t cells that escape the thymus and are inactivated to an unresponsive state by Tregs or fail to be properly stimulated by APCs
A. central tolerance
B. peripheral tolerance

A

B

54
Q

where is central t-cell tolerance occuring?

A

thymus

55
Q

taking a break here

A

PHRM 864 (22 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions